S 2292 · 119th Congress 2025–2027

Over-the-Counter Monograph Drug User Fee Amendments

Latest action · Sep 8, 2025 Placed on Senate Legislative Calendar under General Orders. Calendar No. 152.

Progress

Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.

  1. IntroducedJul 15, 2025
  2. Passed SenateNot reached
  3. Passed HouseNot reached
  4. To the PresidentNot reached
  5. Became lawNot reached

Summary

Over-the-Counter Monograph Drug User Fee Amendments

This bill reauthorizes the Over-the-Counter (OTC) Monograph Drug User Fee Program (OMUFA); revises procedures used by the Food and Drug Administration (FDA) to evaluate topical, nonprescription drugs (e.g., sunscreens); and requires the FDA to clarify the process through which a prescription drug may be switched to nonprescription status.

Under current law, many OTC drugs are marketed through compliance with an OTC monograph issued by the FDA, rather than through an approved new drug application. Monographs establish the conditions under which OTC drugs are generally recognized as safe and effective. The bill reauthorizes the collection of OMUFA fees from OTC drug facilities through FY2030 and revises methods for calculating such fees.

Separately, the bill requires the FDA to allow for the use of real-world evidence to demonstrate the safety and effectiveness of active ingredients in topical, nonprescription drugs. The FDA must consider nonclinical tests and other alternatives to animal testing in evaluating such drugs.

The FDA must also issue guidance to clarify the application process for nonprescription drugs, including applications to switch a prescription drug to nonprescription status. The FDA must plan to engage stakeholders in identifying drugs that are promising candidates for a switch. Moreover, applicants seeking a switch may request to meet with the FDA to develop a plan for the requisite application.

Finally, the Government Accountability Office must report on (1) the OTC monograph drug supply chain, and (2) the FDA’s handling of applications to switch a prescription drug to nonprescription status.

Cosponsors 3

Members who signed on, in the order they did. Signatures ran from Jul 15, 2025 to Jul 29, 2025; 1 is an original cosponsor, there from the day it was introduced.

SeatCosponsorSigned on
D-VATim KaineOriginalJul 15, 2025
D-NJAndy KimJul 29, 2025
R-OHJon HustedJul 29, 2025

Committees 1

Where it was sent and what each committee and subcommittee did with it, in order.

ChamberCommitteeWhat it did
SenateHealth, Education, Labor, and Pensions Committee
Referred Jul 15, 2025Markup Jul 30, 2025Reported Sep 8, 2025

Actions 5

Everything that happened, newest first.

  1. Sep 8, 2025Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute. Without written report.
  2. Sep 8, 2025Placed on Senate Legislative Calendar under General Orders. Calendar No. 152.
  3. Jul 30, 2025Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
  4. Jul 15, 2025Introduced in Senate
  5. Jul 15, 2025Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Related bills 2

Companion bills and other measures the record links to this one.

Titles 3

Every title it has carried, official and short, at each stage.

Official Title as Introduced
A bill to amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user fee program for over-the-counter monograph drugs, and for other purposes.
Short Title(s) as Introduced
Over-the-Counter Monograph Drug User Fee Amendments
Short Title(s) as Reported to Senate
Over-the-Counter Monograph Drug User Fee Amendments

Subjects

Assigned by the Library of Congress. Policy area: Health.

Text 2

Each version as it was printed, newest first.

  1. Sep 8, 2025Reported to Senate
  2. Jul 15, 2025Introduced in Senate

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details.

Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.